Global In Vitro Fertilization Test Market
Global In Vitro Fertilization Test Market

In Vitro Fertilization Test Comprehensive Study by Type (Ovarian Reserve Testing, Semen Analysis, Infectious Disease Screening, Practice (Mock) Embryo Transfer, Uterine Exam) Players and Region - Global Market Outlook to 2026

In Vitro Fertilization Test Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Sep 2021 Edition 245 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is In Vitro Fertilization Test Market?

Before the beginning of IVF, women undergo various screenings or testing. This involves taking a blood sample and testing it for the level of follicle-stimulating hormone.

The market study is being classified by Type (Ovarian Reserve Testing, Semen Analysis, Infectious Disease Screening, Practice (Mock) Embryo Transfer and Uterine Exam) and major geographies with country level break-up.

The Mayo Clinic (United States), ZyMōt Fertility (United States), Monash IVF (Australia), Ferring Pharmaceuticals (Switzerland), CARE Fertility (United Kingdom), CooperSurgical, Inc. (United States), Vitrolife (Sweden), UVA Health (United States) and Merck Group (Germany) are some of the key players profiled in the study.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global In Vitro Fertilization Test market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global In Vitro Fertilization Test market by Type, Application and Region.

On the basis of geography, the market of In Vitro Fertilization Test has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Obesity and Infertility Rate Due to Mental Stress and Change in Eating Habits

Market Trend
  • Increasing Investment for Research and Development of Advanced Technologies and Treatment Methods

Restraints
  • High Cost Associated With In Vitro Fertilization Can Create Hurdles for the Market

Opportunities
  • Increased Adoption of In Vitro Fertilization in Developed Countries

Challenges
  • Less Awareness and Unwillingness to Adopt In Vitro Fertilization in Rural Areas


Market Leaders and some development strategies
In July 2021, Vitrolife acquired Igenomix from the private equity group EQT. Igenomix develops molecular genetic testing diagnostic for reproductive medicine, including in vitro fertilization (IVF) and rare diseases. The acquisition of Igenomix’s portfolio of reproductive genetic testing services along with its IVF device portfolio will allow Vitrolife to offer an IVF platform to potentially deliver personalised genetic information to patients globally and further improve clinical practices in infertility, women’s health, and rare diseases.
In July 2018, Merck launched the QBOX IVF and the new Geri Assess 2.0 to serve the needs of its customers and become the preferred treatment partner for all IVF stakeholders and assisted reproductive treatment (ART) clinics. The new modules help clinics simplify embryo assessment, improve consistency across users and reduce the time spent in annotations by automatically detecting key events in embryo and blastocyst development.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, In Vitro Fertilization Treatment Providers, In Vitro Fertilization Test Drugs & Devices Manufacturers, Suppliers and Distributors of In Vitro Fertilization Test Drugs & Devices, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Which factors would majorly drive the In Vitro Fertilization Test Market?
"Increasing Obesity and Infertility Rate Due to Mental Stress and Change in Eating Habits" is seen as one of major growth factors of In Vitro Fertilization Test Market in years to come.

2. Can we have customized study for In Vitro Fertilization Test Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. Which region will lead the Global In Vitro Fertilization Test Market?
United States will lead In Vitro Fertilization Test Market in coming years.
Report Objectives / Segmentation Covered
By Type
  • Ovarian Reserve Testing
  • Semen Analysis
  • Infectious Disease Screening
  • Practice (Mock) Embryo Transfer
  • Uterine Exam
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Obesity and Infertility Rate Due to Mental Stress and Change in Eating Habits
    • 3.3. Market Challenges
      • 3.3.1. Less Awareness and Unwillingness to Adopt In Vitro Fertilization in Rural Areas
    • 3.4. Market Trends
      • 3.4.1. Increasing Investment for Research and Development of Advanced Technologies and Treatment Methods
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global In Vitro Fertilization Test, by Type and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global In Vitro Fertilization Test (Value)
      • 5.2.1. Global In Vitro Fertilization Test by: Type (Value)
        • 5.2.1.1. Ovarian Reserve Testing
        • 5.2.1.2. Semen Analysis
        • 5.2.1.3. Infectious Disease Screening
        • 5.2.1.4. Practice (Mock) Embryo Transfer
        • 5.2.1.5. Uterine Exam
      • 5.2.2. Global In Vitro Fertilization Test Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Taiwan
          • 5.2.2.2.6. Australia
          • 5.2.2.2.7. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
  • 6. In Vitro Fertilization Test: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. The Mayo Clinic (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ZyMōt Fertility (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Monash IVF (Australia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ferring Pharmaceuticals (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. CARE Fertility (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CooperSurgical, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Vitrolife (Sweden)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. UVA Health (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck Group (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global In Vitro Fertilization Test Sale, by Type and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global In Vitro Fertilization Test (Value)
      • 7.2.1. Global In Vitro Fertilization Test by: Type (Value)
        • 7.2.1.1. Ovarian Reserve Testing
        • 7.2.1.2. Semen Analysis
        • 7.2.1.3. Infectious Disease Screening
        • 7.2.1.4. Practice (Mock) Embryo Transfer
        • 7.2.1.5. Uterine Exam
      • 7.2.2. Global In Vitro Fertilization Test Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Taiwan
          • 7.2.2.2.6. Australia
          • 7.2.2.2.7. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. In Vitro Fertilization Test: by Type(USD Million)
  • Table 2. In Vitro Fertilization Test Ovarian Reserve Testing , by Region USD Million (2015-2020)
  • Table 3. In Vitro Fertilization Test Semen Analysis , by Region USD Million (2015-2020)
  • Table 4. In Vitro Fertilization Test Infectious Disease Screening , by Region USD Million (2015-2020)
  • Table 5. In Vitro Fertilization Test Practice (Mock) Embryo Transfer , by Region USD Million (2015-2020)
  • Table 6. In Vitro Fertilization Test Uterine Exam , by Region USD Million (2015-2020)
  • Table 7. South America In Vitro Fertilization Test, by Country USD Million (2015-2020)
  • Table 8. South America In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 9. Brazil In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 10. Argentina In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 11. Rest of South America In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 12. Asia Pacific In Vitro Fertilization Test, by Country USD Million (2015-2020)
  • Table 13. Asia Pacific In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 14. China In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 15. Japan In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 16. India In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 17. South Korea In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 18. Taiwan In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 19. Australia In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 20. Rest of Asia-Pacific In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 21. Europe In Vitro Fertilization Test, by Country USD Million (2015-2020)
  • Table 22. Europe In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 23. Germany In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 24. France In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 25. Italy In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 26. United Kingdom In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 27. Netherlands In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 28. Rest of Europe In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 29. MEA In Vitro Fertilization Test, by Country USD Million (2015-2020)
  • Table 30. MEA In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 31. Middle East In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 32. Africa In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 33. North America In Vitro Fertilization Test, by Country USD Million (2015-2020)
  • Table 34. North America In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 35. United States In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 36. Canada In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 37. Mexico In Vitro Fertilization Test, by Type USD Million (2015-2020)
  • Table 38. Company Basic Information, Sales Area and Its Competitors
  • Table 39. Company Basic Information, Sales Area and Its Competitors
  • Table 40. Company Basic Information, Sales Area and Its Competitors
  • Table 41. Company Basic Information, Sales Area and Its Competitors
  • Table 42. Company Basic Information, Sales Area and Its Competitors
  • Table 43. Company Basic Information, Sales Area and Its Competitors
  • Table 44. Company Basic Information, Sales Area and Its Competitors
  • Table 45. Company Basic Information, Sales Area and Its Competitors
  • Table 46. Company Basic Information, Sales Area and Its Competitors
  • Table 47. In Vitro Fertilization Test: by Type(USD Million)
  • Table 48. In Vitro Fertilization Test Ovarian Reserve Testing , by Region USD Million (2021-2026)
  • Table 49. In Vitro Fertilization Test Semen Analysis , by Region USD Million (2021-2026)
  • Table 50. In Vitro Fertilization Test Infectious Disease Screening , by Region USD Million (2021-2026)
  • Table 51. In Vitro Fertilization Test Practice (Mock) Embryo Transfer , by Region USD Million (2021-2026)
  • Table 52. In Vitro Fertilization Test Uterine Exam , by Region USD Million (2021-2026)
  • Table 53. South America In Vitro Fertilization Test, by Country USD Million (2021-2026)
  • Table 54. South America In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 55. Brazil In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 56. Argentina In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 57. Rest of South America In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 58. Asia Pacific In Vitro Fertilization Test, by Country USD Million (2021-2026)
  • Table 59. Asia Pacific In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 60. China In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 61. Japan In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 62. India In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 63. South Korea In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 64. Taiwan In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 65. Australia In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 66. Rest of Asia-Pacific In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 67. Europe In Vitro Fertilization Test, by Country USD Million (2021-2026)
  • Table 68. Europe In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 69. Germany In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 70. France In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 71. Italy In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 72. United Kingdom In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 73. Netherlands In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 74. Rest of Europe In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 75. MEA In Vitro Fertilization Test, by Country USD Million (2021-2026)
  • Table 76. MEA In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 77. Middle East In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 78. Africa In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 79. North America In Vitro Fertilization Test, by Country USD Million (2021-2026)
  • Table 80. North America In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 81. United States In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 82. Canada In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 83. Mexico In Vitro Fertilization Test, by Type USD Million (2021-2026)
  • Table 84. Research Programs/Design for This Report
  • Table 85. Key Data Information from Secondary Sources
  • Table 86. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global In Vitro Fertilization Test: by Type USD Million (2015-2020)
  • Figure 5. South America In Vitro Fertilization Test Share (%), by Country
  • Figure 6. Asia Pacific In Vitro Fertilization Test Share (%), by Country
  • Figure 7. Europe In Vitro Fertilization Test Share (%), by Country
  • Figure 8. MEA In Vitro Fertilization Test Share (%), by Country
  • Figure 9. North America In Vitro Fertilization Test Share (%), by Country
  • Figure 10. Global In Vitro Fertilization Test share by Players 2020 (%)
  • Figure 11. Global In Vitro Fertilization Test share by Players (Top 3) 2020(%)
  • Figure 12. Global In Vitro Fertilization Test share by Players (Top 5) 2020(%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. The Mayo Clinic (United States) Revenue, Net Income and Gross profit
  • Figure 15. The Mayo Clinic (United States) Revenue: by Geography 2020
  • Figure 16. ZyMōt Fertility (United States) Revenue, Net Income and Gross profit
  • Figure 17. ZyMōt Fertility (United States) Revenue: by Geography 2020
  • Figure 18. Monash IVF (Australia) Revenue, Net Income and Gross profit
  • Figure 19. Monash IVF (Australia) Revenue: by Geography 2020
  • Figure 20. Ferring Pharmaceuticals (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Ferring Pharmaceuticals (Switzerland) Revenue: by Geography 2020
  • Figure 22. CARE Fertility (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. CARE Fertility (United Kingdom) Revenue: by Geography 2020
  • Figure 24. CooperSurgical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. CooperSurgical, Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Vitrolife (Sweden) Revenue, Net Income and Gross profit
  • Figure 27. Vitrolife (Sweden) Revenue: by Geography 2020
  • Figure 28. UVA Health (United States) Revenue, Net Income and Gross profit
  • Figure 29. UVA Health (United States) Revenue: by Geography 2020
  • Figure 30. Merck Group (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Merck Group (Germany) Revenue: by Geography 2020
  • Figure 32. Global In Vitro Fertilization Test: by Type USD Million (2021-2026)
  • Figure 33. South America In Vitro Fertilization Test Share (%), by Country
  • Figure 34. Asia Pacific In Vitro Fertilization Test Share (%), by Country
  • Figure 35. Europe In Vitro Fertilization Test Share (%), by Country
  • Figure 36. MEA In Vitro Fertilization Test Share (%), by Country
  • Figure 37. North America In Vitro Fertilization Test Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • The Mayo Clinic (United States)
  • ZyMōt Fertility (United States)
  • Monash IVF (Australia)
  • Ferring Pharmaceuticals (Switzerland)
  • CARE Fertility (United Kingdom)
  • CooperSurgical, Inc. (United States)
  • Vitrolife (Sweden)
  • UVA Health (United States)
  • Merck Group (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation